News round-up for 5-9 December by DDW Digital Content Editor Diana Spencer. ‘Teamwork makes the dream work’ this week, with the launch of new partnerships to further the development of precision drugs in neurodevelopmental disorders, lung cancer and rare paediatric diseases. The benefits of collaboration have also been… Read More
A new type of targeted medicine has shown ‘remarkable’ benefits for patients with advanced breast cancer in a major Phase III clinical trial. The drug capivasertib combined with hormone therapy doubled the time it took for cancer to progress in people with advanced forms of the most… Read More
Irish biotech company OmniSpirant and French biotech EVerZom have joined other partners to launch INSPIRE, a €12.8 million lung cancer project funded by Horizon Europe. The project gathers European partners spanning across biotechnology, medical devices, cancer research, academia and patient advocacy. Over the next three years, the consortium… Read More
Myeloma Patients Europe (MPE) has launched an advocacy report on addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE). The report, led by the MPE CEE Workgroup on Access, found huge inequalities for patients, confirming reports from MPE CEE members about a lack of clinical trials… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More
News round-up for 28 November – 2 December by DDW Digital Content Editor Diana Spencer The last seven days have seen breakthroughs announced in malaria treatment, epilepsy and major depressive disorders. The NHS in England has fast tracked another cancer drug, and, in Covid-19 news, researchers have… Read More
The UK government has promised that patients will benefit from cutting-edge new treatments with the introduction of a Vaccine Taskforce style approach to tackling health challenges. The government has committed over £113 ($135) million to fund research into four healthcare missions – cancer, obesity, mental health and addiction. Building… Read More
England will become the first country in Europe to roll out darolutamide (Nubeqa) to patients whose prostate cancer has spread to other parts of the body. The drug works by blocking androgen receptors in cancer cells, which in turn blocks the effect of testosterone that allows the cancer cells to… Read More
Neobe Therapeutics, an early-stage startup, has raised £520K ($628,000) in equity funding to engineer live biotherapeutics to remove barriers to immune infiltration in solid tumours. While immunotherapies have revolutionised the treatment of cancer, the large majority of patients with solid tumours (up to 85%) still do not… Read More
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news. Gene therapies have made the headlines over the last week, with treatments… Read More
Cancer Research UK, The University of Manchester and Roche have opened a multi-drug, precision medicine trial for people with rare cancers. The trial is set up to recruit both paediatric and adult patients with any rare cancer type and is one of very few precision medicine platform… Read More
News round-up for 21-25 November by DDW Digital Content Editor Diana Spencer Gene therapies have made the headlines over the last few days, with treatments for rare AADC deficiency, lung cancer and haemophilia B given the go ahead from regulators. This week has also seen the first… Read More
Scientists have revealed the inner workings of a key protein involved in a wide range of cellular processes – potentially paving the way for better and less toxic cancer drugs. Using Nobel Prize-winning microscopy techniques, the researchers revealed how the tankyrase protein switches itself on and off… Read More
Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution. As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels. James O’Brien, Vice President Life Sciences at Leica Microsystems, said: “Instead of spending… Read More
Cancer Research UK’s innovation engine, Cancer Research Horizons, and Newcastle University, have agreed an extension of their strategic drug discovery alliance with Astex Pharmaceuticals. The alliance will continue to focus on the discovery of potential new cancer drugs with associated biomarkers, with the aim of providing an… Read More
Cancer is supported by complex ecosystems within the body which can be disrupted by cutting-edge new treatments and cures, cancer researchers have concluded. The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have revealed plans to direct research against the cells, signals and… Read More
